Search Results

You are looking at 111 - 120 of 403 items for :

  • "bevacizumab" x
  • Refine by Access: All x
Clear All
Full access

Ten Years of Progress Against Breast Cancer: A Partnership of Basic and Clinical/Translational Science

Robert W. Carlson and on behalf of the NCCN Breast Cancer Panel

–Vascular Endothelial Growth Factor Therapy Perhaps no other area of breast oncology has been as controversial over the past decade as the potential role of bevacizumab, a humanized monoclonal antibody against vascular endothelial growth factor, in combination with

Full access

NCCN Guidelines Insights: Cervical Cancer, Version 1.2020

Featured Updates to the NCCN Guidelines

Nadeem R. Abu-Rustum, Catheryn M. Yashar, Sarah Bean, Kristin Bradley, Susana M. Campos, Hye Sook Chon, Christina Chu, David Cohn, Marta Ann Crispens, Shari Damast, Christine M. Fisher, Peter Frederick, David K. Gaffney, Robert Giuntoli II, Ernest Han, Warner K. Huh, John R. Lurain III, Andrea Mariani, David Mutch, Christa Nagel, Larissa Nekhlyudov, Amanda Nickles Fader, Steven W. Remmenga, R. Kevin Reynolds, Rachel Sisodia, Todd Tillmanns, Stefanie Ueda, Renata Urban, Emily Wyse, Nicole R. McMillian, and Angela D. Motter

regimens (eg, bevacizumab, pembrolizumab) in combination with, or as alternatives to, existing first- and second-line treatment options has led to improved outcomes in some patients. These NCCN Guidelines Insights focus on recent changes to first- and

Full access

Using Cellular Mechanisms to Develop Effective Combinations of Photodynamic Therapy and Targeted Therapies

Tayyaba Hasan

consequence of PDT,” she revealed. Overexpression of VEGF seems to contribute to the growth and metastasis of cancers. Therefore, the VEGF pathway represents a prime area for therapeutic intervention, because drugs such as bevacizumab (Avastin) may inhibit

Full access

Updates to the Management of Kidney Cancer

Eric Jonasch

bevacizumab was compared with sunitinib in 950 patients in the IMmotion 151 trial. 9 Patients were stratified according to MSKCC risk score, liver metastases, and PD-L1 status. Of these, 40% were positive for PD-L1. Median PFS was 11.2 months for the

Full access

Off-Label Use of Oncology Drugs: Too Much, Too Little, or Just Right?

Harold J. Burstein

constitute what most observers would consider appropriate use. The 10 drugs in this analysis (albumin-bound paclitaxel, azacytidine, bevacizumab, bortezomib, cetuximab, docetaxel, gemcitabine, pemetrexed, rituximab, and trastuzumab) are products well

Full access

In Defense of Hepatic Arterial Infusion for Hepatic Metastases of Colorectal Cancer

Nancy Kemeny

. 11. Giantonio BJ Catalano PJ Meropol NJ . Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200

Full access

NCCN Guidelines® Updates: Kidney Cancer

Certain Circumstances: ∘ “Bevacizumab .... and renal cell cancer carcinoma (HLRCC)- associated RCC ” was revised.

Full access

QIM22-203: Randomized Trial of Implementing a Clinical Decision Support Tool for Automatic Selection of Payor-Mandated Biosimilar at Time of Prescribing

Shayna Simon, Lindsey Skelton, Sherry F. Parker, Rebecca Brian, Waddah Arafat, and Muhammad Shaalan Beg

tool is being validated for two additional oncology reference products (bevacizumab, trastuzumab). EMR based tools can help manage the complexity of ordering biosimilars in the current healthcare system.

Full access

BPI20-012: Relative Risk of Various Endocrinopathies Associated With the Use of Immune Checkpoint Inhibitors in the First-Line Treatment of Advanced Renal Cell Carcinoma: a Systematic Review and Meta-Analysis

Nusrat Jahan, Francis Mogollon-Duffo, Miguel Quirch, Somedeb Ball, Fred Hardwicke, Lukman Tijani, and Shabnam Rehman

. For hypophysitis and diabetes, CheckMate 214 and KEYNOTE-426 including 1936 patients were analyzed. ICI regimens used in the study arms are — CheckMate 214: nivolumab + ipilimumab; IMmotion151: atezolizumab + bevacizumab; JAVELIN Renal 101: axitinib

Full access

QIM22-198: Optimizing a Systemic Platform to Standardize Oncologic Biosimilars Utilization at Cedars-Sinai Medical Center (CSMC)

Suwicha Limvorasak, Hilary Teaford, Crystal Leung Dobbs, Kyung Kim, Marcio A. Diniz, Andre Rogatko, Edwin M. Posadas, Kevin S. Scher, Vipul Patel, Bruce Vinson, Leanne Sakamoto, Rita Shane, Robert A. Figlin, and Karen L. Reckamp

substitution within the electronic order set. For this interim report, we identified adult cancer patients who initiated treatment with bevacizumab, rituximab or trastuzumab between January to October 2021 through electronic health record. Conversion rate was